Bioenergetic pathways in tumor mitochondria as targets for cancer therapy and the importance of the ROS-induced apoptotic trigger

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F86652036%3A_____%2F10%3A00349341" target="_blank" >RIV/86652036:_____/10:00349341 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Bioenergetic pathways in tumor mitochondria as targets for cancer therapy and the importance of the ROS-induced apoptotic trigger

Popis výsledku v původním jazyce

Mitochondria are emerging as idealized targets for anti-cancer drugs. Although they are inherent to all cells, drugs are being developed that selectively target the mitochondria of malignant cells without adversely affecting normal cells. Such anti-cancer drugs destabilizing mitochondria are referred to as mitocans, classified into several groups according to their mode of action and the location or nature of their specific targets. Many mitocans selectively interfere with the functions of cancer cell mitochondria, causing major disruptions often associated with overloads in ROS production leading to the induction of apoptosis. A common theme emerging is that mitochondrially mediated ROS activation as an apoptosis trigger offers a powerful basis for cancer therapy. Continued research is likely to identify increasing numbers of novel agents that should prove highly effective against a variety of cancers, circumventing tumor resistance to the other more established approaches

Název v anglickém jazyce

Bioenergetic pathways in tumor mitochondria as targets for cancer therapy and the importance of the ROS-induced apoptotic trigger

Popis výsledku anglicky

Mitochondria are emerging as idealized targets for anti-cancer drugs. Although they are inherent to all cells, drugs are being developed that selectively target the mitochondria of malignant cells without adversely affecting normal cells. Such anti-cancer drugs destabilizing mitochondria are referred to as mitocans, classified into several groups according to their mode of action and the location or nature of their specific targets. Many mitocans selectively interfere with the functions of cancer cell mitochondria, causing major disruptions often associated with overloads in ROS production leading to the induction of apoptosis. A common theme emerging is that mitochondrially mediated ROS activation as an apoptosis trigger offers a powerful basis for cancer therapy. Continued research is likely to identify increasing numbers of novel agents that should prove highly effective against a variety of cancers, circumventing tumor resistance to the other more established approaches

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

EB - Genetika a molekulární biologie

OECD FORD obor

—

Projekt

—

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2010

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Molecular Aspects of Medicine

ISSN

0098-2997

e-ISSN

—

Svazek periodika

31

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

31

Strana od-do

—

Kód UT WoS článku

000276729700003

EID výsledku v databázi Scopus

—